Creating new targeted combination therapies for patients with prostate cancer that has spread outside the prostate (metastatic)

University of East AngliaProfessor Colin Cooper£250,0002013 - 2016

The project in a nutshell

Creating a new treatment of advanced/metastatic prostate cancer that uses tiny nanoparticles to deliver both a drug that weakens prostate cancer cells and standard chemotherapy drug docetaxel at the same time.

Why we funded it

Currently docetaxel is one of the last treatment options available for men with metastatic prostate cancer, but many develop resistance to the drug. The results of this research could lead to better results and longer survival for men with advanced prostate cancer.

For more detailed information on this project, please look at the lay summary